Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inho Kim

Showing results (311-320 of 347) with videos related to

Pageof 35
Sort By:
Blood|March 29, 2020
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trialAndrew H Wei, Pau Montesinos, Vladimir Ivanov, et al.
Journal of Korean Medical Science|February 20, 2014
Prevention of venous thromboembolism, 2nd edition: Korean Society of Thrombosis and Hemostasis Evidence-based Clinical Practice GuidelinesSoo-Mee Bang, Moon Ju Jang, Kyoung Ha Kim, et al.
Blood Cancer Journal|October 2, 2021
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
The New England Journal of Medicine|May 31, 2024
Asciminib in Newly Diagnosed Chronic Myeloid LeukemiaAndreas Hochhaus, Jianxiang Wang, Dong-Wook Kim, et al.
Cancer Genetics and Cytogenetics|December 16, 2010
Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridizationHye Ryun Lee, Bora Oh, Dae Sik Hong, et al.
Cancer Genetics and Cytogenetics|December 16, 2010
GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridizationYoungil Koh, Dae-Young Kim, Sung-Hyo Park, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 4, 2019
Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring SystemKi Sun Jung, Yoo-Jin Kim, Yeo-Kyeoung Kim, et al.
Acta Haematologica|December 5, 2012
RANTES polymorphisms and the risk of graft-versus-host disease in human leukocyte antigen-matched sibling allogeneic hematopoietic stem cell transplantationDong-Yeop Shin, Inho Kim, Jin Hee Kim, et al.
Therapeutic Drug Monitoring|December 1, 2017
Early Therapeutic Drug Monitoring of Posaconazole Oral Suspension in Patients With Hematologic MalignanciesHyeon Jeong Suh, Inho Kim, Joo-Youn Cho, et al.
Haematologica|July 2, 2026
Favorable tolerability of asciminib <i>versus</i> ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemiaGhayas C Issa, Richard A Larson, Timothy P Hughes, et al.
Pageof 35

Showing results (311-320 of 347) with videos related to

Sort By:
Pageof 35
Blood|March 29, 2020
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trialAndrew H Wei, Pau Montesinos, Vladimir Ivanov, et al.
Journal of Korean Medical Science|February 20, 2014
Prevention of venous thromboembolism, 2nd edition: Korean Society of Thrombosis and Hemostasis Evidence-based Clinical Practice GuidelinesSoo-Mee Bang, Moon Ju Jang, Kyoung Ha Kim, et al.
Blood Cancer Journal|October 2, 2021
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
The New England Journal of Medicine|May 31, 2024
Asciminib in Newly Diagnosed Chronic Myeloid LeukemiaAndreas Hochhaus, Jianxiang Wang, Dong-Wook Kim, et al.
Cancer Genetics and Cytogenetics|December 16, 2010
Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridizationHye Ryun Lee, Bora Oh, Dae Sik Hong, et al.
Cancer Genetics and Cytogenetics|December 16, 2010
GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridizationYoungil Koh, Dae-Young Kim, Sung-Hyo Park, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 4, 2019
Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring SystemKi Sun Jung, Yoo-Jin Kim, Yeo-Kyeoung Kim, et al.
Acta Haematologica|December 5, 2012
RANTES polymorphisms and the risk of graft-versus-host disease in human leukocyte antigen-matched sibling allogeneic hematopoietic stem cell transplantationDong-Yeop Shin, Inho Kim, Jin Hee Kim, et al.
Therapeutic Drug Monitoring|December 1, 2017
Early Therapeutic Drug Monitoring of Posaconazole Oral Suspension in Patients With Hematologic MalignanciesHyeon Jeong Suh, Inho Kim, Joo-Youn Cho, et al.
Haematologica|July 2, 2026
Favorable tolerability of asciminib <i>versus</i> ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemiaGhayas C Issa, Richard A Larson, Timothy P Hughes, et al.
Pageof 35